Gene editing for very high triglycerides
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new one-time gene-editing treatment (CS-121) for people with very high triglycerides that don't lower enough with standard medicines. The treatment aims to reduce triglycerides and could help prevent pancreatitis and heart problems, but it is an early-stage gene therapy with strict safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 18 and 64.
- You have very high triglycerides (a type of fat) in your blood—at least 500 mg/dL—despite taking standard treatments.
- You have had at least 3 blood tests in the last 2 years showing this high level, and at least 2 tests on different days during the screening period.
- If you can become pregnant, you must agree to use effective contraception and have a negative pregnancy test.
- You have not had acute pancreatitis within the last 4 weeks, nor a recent heart attack or heart procedure (like stenting) in the last 6 months.
- You do not have certain serious health conditions, such as major organ disease, a history of cancer, or recent major surgery (within 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication called DR10624 for people with very high triglycerides, a type of fat in the blood that can increase the risk of heart problems and pancreatitis. The trial aims to see if this drug can safely lower triglycerides better than standard care.
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This study tests a new gene-editing treatment called CS-121 for people with FCS whose triglycerides remain very high despite standard therapy. It aims to lower triglyceride levels by editing the APOC3 gene.
This trial tests a new gene-editing treatment (CS-121) for children and teens with a rare inherited condition called Familial Chylomicronemia Syndrome (FCS). It aims to lower very high triglyceride levels and reduce the risk of pancreatitis.
This Phase 1 trial tests the safety of a gene therapy for people with inherited, hard-to-control high triglycerides (fat in the blood) who have had pancreatitis episodes. It may help by targeting the genes involved in triglyceride control, but the main goal here is to check safety and tolerability.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
Hear when a new Severe Hypertriglyceridemia (sHTG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.